RenovoRx, Inc.
RNXT- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001574094
No open-market purchases or sales by RenovoRx, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $9.00M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding RenovoRx, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 14 | 12 | −2 |
| Shares | 363.6K | 331.2K | −32.5K (−8.9%) |
| Value | $473.5K | $758.1K | +$284.6K (+60.1%) |
New holders (4)
Institutions that held RenovoRx, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nixon Peabody Trust Co | 97,165 | $222.5K | 0.02% |
| HRT Financial LP | 14,041 | $32.0K | 0.00% |
| Bank of America Corp | 118 | $270 | 0.00% |
| Royal Bank of Canada | 101 | $0 | 0.00% |
Sold out (6)
Institutions that held RenovoRx, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Cohen Lawrence B | 97,165 | $129.2K |
| Level Four Advisory Services, LLC | 15,000 | $19.9K |
| Ground Swell Capital, LLC | 11,481 | $14.5K |
| Susquehanna International Group, LLP | 10,340 | $13.0K |
| Morgan Stanley | 176 | $234 |
| JPMorgan Chase & Co | 9 | $11 |